Clinical trial Recruiting at 4 sites Interventional Ages 18 and up

Evaluating new methods for assessing coronary artery disease after procedures

Official title: Postprocedural Contrast Mediated FFR Plus Intracoronary Infusion of Nitroglycerin in Multivessel Patients

Run by Fundación EPIC · NCT06273293 · Data updated 2026-11-12

This study is testing a new way to check for coronary artery disease in patients with multiple blocked arteries to see if it works better than the usual method after they have heart procedures.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment150 (estimated)
SponsorFundación EPIC
Academic / other
Locations4 sites (Alicante and 3 other locations)
StatusRecruiting
StartedMay 31, 2024
Main results expectedDecember 20, 2026
Study endsJanuary 20, 2027
Registry record updatedFebruary 17, 2026
Trial IDNCT06273293 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults over 18 with multivessel coronary artery disease requiring percutaneous coronary revascularization.

Probably not a fit

Patients with contraindications to adenosine or significant comorbidities limiting life expectancy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of using a new method called cFFR-NTG for assessing coronary artery disease in patients with multivessel conditions. It aims to improve the management of intermediate coronary lesions by comparing this method to the traditional fractional flow reserve (FFR) technique, which often requires adenosine. The study will involve patients undergoing percutaneous coronary intervention (PCI) and will utilize a specialized pressure microcatheter for both diagnosis and post-procedure evaluation. By focusing on patients with significant stenosis in multiple vessels, the trial seeks to enhance therapeutic decision-making and patient outcomes.

Why it matters

Potential benefit: If successful, this approach could lead to better management of coronary artery disease and reduced risk of future cardiovascular events for patients.

How similar studies have gone: Other studies have shown promise with similar approaches, particularly in improving outcomes for patients with coronary artery disease.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients \>18 years old and,
* Patients with multivessel coronary artery disease (multivessel coronary artery disease will be considered the presence of significant stenosis in 2 or more first or second order vessels greater than 1.5 mm in diameter with an angiographic reduction of their diameter ≥50% by visual estimation) subsidiary of percutaneous coronary revascularization in at least one of them and,
* Use of Navvus pressure microcatheter both for functional diagnosis and for post-PCI evaluation of the different vessels and,
* Patients who have signed the Informed Consent.

Exclusion Criteria:

* Patients with intolerance or contraindication to adenosine.
* Hemodynamically unstable patients, acute phase of a STEACS.
* Patient with significant comorbidity with limited life expectancy.
* Patients with the patient's express refusal to participate in the study.
* Pregnant or breastfeeding female patients.

Where it's running

  • Hospital Universitario San Juan de Alicante
    Alicante, Spain
    Recruiting
  • Hospital Universitario de Badajoz
    Badajoz, Spain
    Recruiting
  • Hospital Universitario Juan Ramón Jiménez
    Huelva, Spain
    Recruiting
  • Hospital Universitario Virgen del Rocío
    Seville, Spain
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.